Lentiviral vector transduced CD34+ cells Therapy

N/A

Report date: 2023/10/26 17:00:15

Base Information

Drug NameLentiviral vector transduced CD34+ cells Therapy
Drug Alias Namep47LV transduced autologous CD34+ cells
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionHematopoietic progenitor cell antigen CD34 modulators
TargetsHematopoietic progenitor cell antigen CD34
Therapy Area/IndicationsGranulomatous Disease, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGreat Ormond Street Hospital For Children Nhs Foundation Trust
China Registration ClassN/A

Develop Information

Active CompaniesGreat Ormond Street Hospital For Children Nhs Foundation Trust
Inactive CompaniesN/A
Active IndicationsGranulomatous Disease, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A